Cure Today2d
Personalized Medicine Makes Strides Across the GU Oncology Treatment Space
Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.
AstraZeneca Rises Almost 9% in a Month: How to Play the Stock
AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...
pharmaphorum4d
Boehringer eyes third quarter FDA verdict for oral HER2 drug
AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has accelerated approval as a second-line treatment for HER2-mutated NSCLC and is dosed ...
Cure Today5d
Understanding the FDA Approval of Enhertu in HER2-Low and -Ultralow Breast Cancer
Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...
precisionmedicineonline5d
FDA Accepts Boehringer Ingelheim's New Drug Application for HER2-Targeted Therapy in NSCLC
In a Phase Ib trial, 71 percent of patients responded to zongertinib and lived a median six months before disease progression or death.
Targeted Oncology6d
Targeted Therapy Options for Gastric/GEJ Cancers Expand
Ronan J. Kelly, MD, MBA, discusses the targeted therapy options that have become available for patients with gastric, ...